drugset / Trial / NCT00271258

Safety Study of Sodium Divalproate in Bipolar Disorder in Adolescents

NCT00271258 ↗

Phase 3 Completed 200 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

\- Main objective: To evaluate the clinical and physiological tolerance of sodium divalproate in manic, mixed or hypomanic episodes of bipolar disorder in adolescents treated for 6 months. \- Secondary objective: To evaluate the efficacy of sodium divalproate in improving manic, mixed or hypomanic symptoms.

Timeline

Start
2005-01
Primary completion
—
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject sodium divalproate Unknown — —

Indications